Afaaf Liberty to HIV Integrase Inhibitors
This is a "connection" page, showing publications Afaaf Liberty has written about HIV Integrase Inhibitors.
Connection Strength
0,252
-
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. N Engl J Med. 2021 12 30; 385(27):2531-2543.
Score: 0,192
-
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial. Lancet HIV. 2025 Mar; 12(3):e201-e213.
Score: 0,060